WINTON GROUP Ltd cut its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) by 39.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 9,818 shares of the company’s stock after selling 6,510 shares during the period. WINTON GROUP Ltd’s holdings in Reata Pharmaceuticals were worth $298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System increased its position in Reata Pharmaceuticals by 6.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 13,787 shares of the company’s stock worth $419,000 after buying an additional 800 shares during the period. Integral Health Asset Management LLC increased its position in Reata Pharmaceuticals by 198.2% in the second quarter. Integral Health Asset Management LLC now owns 104,369 shares of the company’s stock worth $3,172,000 after buying an additional 69,369 shares during the period. DekaBank Deutsche Girozentrale increased its position in Reata Pharmaceuticals by 36.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 22,640 shares of the company’s stock worth $710,000 after buying an additional 6,000 shares during the period. Emerald Mutual Fund Advisers Trust increased its position in Reata Pharmaceuticals by 15.3% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 251,268 shares of the company’s stock worth $7,636,000 after buying an additional 33,262 shares during the period. Finally, Emerald Advisers LLC increased its position in Reata Pharmaceuticals by 5.7% in the second quarter. Emerald Advisers LLC now owns 286,181 shares of the company’s stock worth $8,697,000 after buying an additional 15,335 shares during the period. 76.00% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on RETA. The Goldman Sachs Group increased their target price on Reata Pharmaceuticals from $76.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, November 9th. Robert W. Baird raised their price target on Reata Pharmaceuticals to $40.00 in a report on Tuesday, November 15th. StockNews.com started coverage on Reata Pharmaceuticals in a report on Wednesday, October 12th. They set a “sell” rating on the stock. Guggenheim started coverage on Reata Pharmaceuticals in a report on Wednesday, October 19th. They set a “buy” rating and a $75.00 price target on the stock. Finally, Barclays raised their price target on Reata Pharmaceuticals from $43.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, November 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $64.75.
Reata Pharmaceuticals Stock Up 7.2 %
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.19. Reata Pharmaceuticals had a negative return on equity of 322.32% and a negative net margin of 9,897.91%. The business had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.43 million. On average, sell-side analysts anticipate that Reata Pharmaceuticals, Inc. will post -8.38 earnings per share for the current year.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.